- Home
- SNTI vs XCUR Comparison
SNTI vs XCUR Comparison
Compare SNTI & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNTI | XCUR |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | United States | United States |
| Employees | N/A | 8 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.5M | 26.6M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SNTI | XCUR |
|---|---|---|
| Price | $0.86 | $4.19 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 101.7K | 18.2K |
| Earning Date | 05-05-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 77.31 | ★ 83.37 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7,627.27 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.77 | $3.10 |
| 52 Week High | $5.10 | $13.37 |
Technical Indicators
Market Signals| Indicator | SNTI | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | 44.87 | 49.32 |
| Support Level | $0.80 | $3.40 |
| Resistance Level | $1.02 | $4.34 |
| Average True Range (ATR) | 0.06 | 0.35 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 40.73 | 21.30 |
Price Performance
Historical ComparisonAbout SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About XCUR Exicure Inc.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.